Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
